Literature DB >> 1730721

In vitro activity of the transcription activation functions of the progesterone receptor. Evidence for intermediary factors.

L Shemshedini1, J W Ji, C Brou, P Chambon, H Gronemeyer.   

Abstract

The human progesterone receptor (hPR) is a ligand-dependent transcription factor which contains two distinct transcription activation functions (TAFs). The full-length hPR and its individual TAFs were overexpressed in the baculovirus system and tested in a HeLa cell-derived in vitro transcription system. hPR stimulated transcription in a ligand-independent manner. When the two TAFs fused to the DNA-binding domain of GAL4 were tested, only the constitutive TAF-1 was functional in vitro, strongly suggesting that the transcriptional activity of baculovirus-expressed hPR comes solely from TAF-1. The GAL-TAF-1 activator was found to self-squelch without affecting basal transcription. A partially purified fraction relieved this self-squelching and, moreover, stimulated transcriptional activation by GAL-TAF-1, while having no influence on basal transcription. These results strongly suggest that the transcriptional activity of GAL-TAF-1 requires a factor(s) distinct from the general transcription factors.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730721

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily.

Authors:  Z Nawaz; D M Lonard; C L Smith; E Lev-Lehman; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  Stimulation of transcription in vitro from a liver-specific promoter by human glucocorticoid receptor (hGRalpha).

Authors:  G Schweizer-Groyer; F Cadepond; N Jibard; E Neau; I Segard-Maurel; E E Baulieu; A Groyer
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

3.  Delineation of a small region within the major transactivation domain of the human glucocorticoid receptor that mediates transactivation of gene expression.

Authors:  K Dahlman-Wright; T Almlöf; I J McEwan; J A Gustafsson; A P Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

4.  Antiprogestins prevent progesterone receptor binding to hormone responsive elements in vivo.

Authors:  M Truss; J Bartsch; M Beato
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

5.  Ligand-dependent activation of transcription in vitro by retinoic acid receptor alpha/retinoid X receptor alpha heterodimers that mimics transactivation by retinoids in vivo.

Authors:  F J Dilworth; C Fromental-Ramain; E Remboutsika; A Benecke; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

6.  p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation.

Authors:  W L Kraus; J T Kadonaga
Journal:  Genes Dev       Date:  1998-02-01       Impact factor: 11.361

7.  An indirect negative autoregulatory mechanism involved in hepatocyte nuclear factor-1 gene expression.

Authors:  A A Kritis; E Ktistaki; D Barda; V I Zannis; I Talianidis
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

8.  Oestrogen receptor facilitates the formation of preinitiation complex assembly: involvement of the general transcription factor TFIIB.

Authors:  M Sabbah; K I Kang; L Tora; G Redeuilh
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

9.  The glucocorticoid receptor hormone binding domain mediates transcriptional activation in vitro in the absence of ligand.

Authors:  J Schmitt; H G Stunnenberg
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

10.  Purified cofactors and histone H1 mediate transcriptional regulation by CTF/NF-I.

Authors:  Y Dusserre; N Mermod
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.